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Supplementary Table 1. Demographics and baseline values for 45 healthy participants (Groups A and B) and 15 with diabetic macular oedema 
(Group C). 
 Group A  Group B  Group C 
 n   mean (SD) range n    mean (SD) range n    mean (SD) range 
Age (years)   21   22.52 (3.66) 18 - 30 24    56.96 (5.07) 50 - 68 15 56.07 (10.15) 32 - 74 
Gender (m:f)  21        12:9  24           7:17  15 11:4  
PVT NL (number)  21     4.55 (4.57)   0 - 18 24     4.29 (5.21)   0 - 24 15 5.53 (5.97)   1 - 21 
PVT RT (msec)  21 343.99 (46.78) 270.89 - 455.90 24 340.52 (46.78) 276.15 - 456.63 15 353.13 (43.88) 280.13 - 429.75 
KSS (score)  21      3.43 (1.69) 1 - 7 24     2.42 (1.06) 1 - 5 15 2.93 (1.44) 1 - 7 
PSQ (score)  21      2.62 (2.27) 0 - 8 24     3.58 (2.24) 1 - 9 15 4.33 (2.66) 1 - 11 
CESD (score)  21      4.33 (3.77)   0 - 16 24     3.71 (4.28)   0 - 13 15 7.60 (6.14)   0 - 20 
GHQ12 (score)  21  6.95 (2.65)  4 - 15 24 6.67 (2.20) 3 - 12 15 8.13 (2.61) 5 - 14 
BCVA (letters)  21   90.67 (3.23) 85 - 96 24   89.50 (3.09) 83 - 95 15 86.47 (5.17) 79 - 94 
CS (letters) 20§   41.10 (1.74) 36 - 42  23§   40.87 (1.91) 35 - 42 15 35.07 (3.33) 30 - 41 
CCT protan (10-4 u’v’)  21   57.43 (18.73) 22 - 95  23§   64.17 (13.94) 40 - 86 15 145.80 (79.85) 42 - 353 
CCT deutan (10-4 u’v’)  21   51.38 (17.60) 26 - 97  23§   65.48 (18.37)   39 - 122 15 132.27 (91.27)   55 - 411 
CCT tritan (10-4 u’v’)  21   64.43 (20.66)   33 - 106  23§   82.70 (32.87)   29 - 158 15 213.60 (118.42) 34 - 488 
mfERG amp 1 (μV) 20§   66.40 (16.75)   36.10 - 108.00 24   66.16 (12.96) 44.90 - 99.50 15 51.07 (12.90) 26.70 - 70.10 
mfERG lat 1 (msec) 20§   35.64 (2.09) 31.50 - 40.20 24   36.29 (1.76) 33.40 - 40.20 15 38.23 (1.88) 35.40 - 41.30 
EOG (ratio)  21     2.42 (0.49) 1.77 - 3.75 24     2.21 (0.39) 1.60 - 3.00 15 2.38 (0.58) 1.70 - 3.60 
MP1 (dB)  19   19.59 (1.10) 15.60 - 21.00 23   19.32 (1.25) 15.40 - 20.00 15 14.08 (3.04) 6.60 – 17.80 
OCT CST (μm)   21 277.33 (19.52) 238  - 319 24 282.71 (19.63) 254 - 319 15 316.27 (32.65) 274 - 389 
OCT thickness in field 
of max pathology (μm) 
      15 362.87 (31.83) 327 - 439 
BP systolic (mmHg) ^       13 132.38 (13.82) 110 - 162 
BP diastolic (mmHg) ^       13 78.85 (10.49) 60 - 94 
HbA1c (mmol/mol) ^       14 66.37 (23.26) 39 - 114 
Cholesterol (mmol/L) ^       14 4.7 (0.96) 3.1 – 6.3 
eGFR ^       13 72.31 (19.89) 36 - 90 
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§ one participant in each group was unable to perform some procedures; ^ measured  at screening visit 
Legend: BCVA = best corrected visual acuity; CCT = Cambridge color vision test; CESD = The Centre for Epidemiologic Studies Depression scale; 
CS = contrast sensitivity; EOG = electro-oculogram; GHQ12 = General Health Questionnaire; KSS = Karolinska Sleep Scale; mfERG = multifocal 
electroretinogram; MP1 = microperimetry; OCT CST = optical coherence tomography central subfield thickness; PSQ = Pittsburgh Sleep Quality 
Index; PVT NL = Psychomotor Vigilance Task number of lapses; PVT RT = Psychomotor Vigilance Task response time 
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Supplementary Table 2: Specified adverse events reported by 55 participants who completed at least 1 month of follow-up shown by 
participant and event. 
 
 Group A (n=20) Group B (n=20) Group C (n=15) 





Totals 15 41 15 64 6 9 
Ocular        
Red eyes 0 0 2 3 0 0 
Eye soreness 2 2 3 6 0 0 
Eye pain 1 1 1 1 0 0 
Eyelid swelling  1 1 3 4 0 0 
Pressure signs from mask  0 0 1 1 0 0 
‘Heavy eyelids’ 0 0 1 1 0 0 
Itchy eyes 1 1 2 2 1 1 
Dry eyes 0 0 2 5 1 1 
Watery eyes 1 1 1 1 0 0 
Loss of eyelashes 0 0 1 1 0 0 
Double vision 0 0 1 1 0 0 
Blurred vision 1 1 0 0 0 0 
Photophobia 1 1 0 0 0 0 
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Corneal foreign body 0 0 1 1 0 0 
Mask related adverse events       
General mask discomfort 3 3 2 2 0 0 
Soreness around ears 2 3 1 2 0 0 
Ear pain 2 3 0 0 0 0 
Mask digging into bridge of the nose 1 1 3 5 0 0 
Mask pressing on eye socket 1 1 1 1 0 0 
Mask too hot on face 4 6 1 3 0 0 
Due to light brightness 2 3 1 1 0 0 
Rubbing of the mask Velcro 1 2 2 2 0 0 
Straps rubbing the ears 1 2 1 1 0 0 
Label at the back of the mask strap 0 0 1 1 0 0 
Pressure on temporal area 1 1 0 0 0 0 
Pressure on eyes 1 1 0 0 0 0 
Sleep disturbance       
Change in sleep pattern  0 0 1 1 2 2 
Due to mask slipping off 1 1 1 1 0 0 
Other        
Myocardial infarction 0 0 0 0 1 1 
Angina 0 0 0 0 1 1 
Pneumonia 0 0 1 1 0 0 
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Viral respiratory infection 0 0 1 1 0 0 
Skin rash on the cheeks (associated 
with viral respiratory infection) 0 0 1 1 0 0 
Gastroenteritis 0 0 1 1 1 1 
Back pain 0 0 1 1 0 0 
Migraine 3 4 0 0 1 1 
Headaches 1 1 2 2 0 0 
Dental pain  (after tooth extraction) 1 1 0 0 0 0 
Nausea after electrodiagnostic tests 0 0 1 3 0 0 
Nausea during microperimetry test 0 0 1 1 0 0 
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Supplementary Table 3  Number of lapses (NL) on psychomotor vigilance task tests for participants crossing abnormal criteria during the 
study. Abnormal values are underlined. 
 










7 66 31 7 17 31 40 39 
13 20 17 1 0 12 4 23 
15 21 17 14 30 21 24 30 
45 60 26 8 20 25 18 27 
49 19 17 18 9 16 27 37 
72 53 26 9 19 28   
94 61 26 21 14 11 21 27 
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Supplementary Table 4 Response time (RT) on psychomotor vigilance task tests for participants crossing the abnormal criterion during the 
study. Abnormal values are underlined. 
 








 month  
4 
7 66 460 389 432 470 491 485 
13 20 460 317 333 416 367 420 
15 21 460 406 454 434 435 453 
45 60 460 391 433 441 445 466 
49 19 460 418 339 411 442 478 
72 53 460 409 446 459   
75 52 460 430 441 463 436 423 
 
